Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

The Cyclin-dependent kinase 4 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development Cyclin-dependent kinase 4, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Cyclin-dependent kinase 4 and features dormant and discontinued projects.

Key Therapy Areas in the Cyclin-dependent kinase 4 Pipeline Drugs Market

The key therapy areas in the Cyclin-dependent kinase 4 pipeline drugs market are Oncology, Infectious disease, Toxicology, Undisclosed, and Genetic Disorders.

 Cyclin-dependent kinase 4 Drugs Market, by Therapy Areas

 Cyclin-dependent kinase 4 Drugs Market, by Therapy Areas

For more target insights, download a free report sample

Key MoA in the Cyclin-dependent kinase 4 Pipeline Drugs Market

The key mechanism of action in the Cyclin-dependent kinase 4 pipeline drugs market is Cyclin Dependent Kinase 4 Inhibitor.

Cyclin-dependent kinase 4 Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Cyclin-dependent kinase 4 pipeline drugs market are Intravenous, and Oral.

Cyclin-dependent kinase 4 Pipeline Drugs Market, by RoA

Cyclin-dependent kinase 4 Pipeline Drugs Market, by RoA

For more company insights, download a free sample report

Key Molecule Types in the Cyclin-dependent kinase 4 Pipeline Drugs Market

The key molecule types in Cyclin-dependent kinase 4 pipeline drugs market are Monoclonal Antibody, and Small Molecule.

Cyclin-dependent kinase 4 Pipeline Drugs Market, by Major Molecules

Cyclin-dependent kinase 4 Pipeline Drugs Market, by Major Molecules

For more company insights, download a free sample report

Major Companies in the Cyclin-dependent kinase 4 Pipeline Drugs Market

The major companies in the Cyclin-dependent kinase 4 pipeline drugs market are G1 Therapeutics Inc, Travecta Therapeutics Inc, ViroStatics SRL, Sanofi, Tetranov International Inc, Shanghai Pharmaceutical Group Co Ltd, Sihuan Pharmaceutical Holdings Group Ltd, and Sino Biopharmaceutical Ltd among others.

 Cyclin-dependent kinase 4 Pipeline Drugs Market, by Major Companies

 Cyclin-dependent kinase 4 Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Cyclin-dependent kinase 4 Pipeline Drugs Market Overview

Key Therapy Areas Oncology, Infectious disease, Toxicology, Undisclosed, and Genetic Disorders
Key Mechanisms of action Cyclin Dependent Kinase 4 Inhibitor
Key Routes of Administration Intravenous, and Oral
Key molecule types Monoclonal Antibody, and Small Molecule
Major companies G1 Therapeutics Inc, Travecta Therapeutics Inc, ViroStatics SRL, Sanofi, Tetranov International Inc, Shanghai Pharmaceutical Group Co Ltd, Sihuan Pharmaceutical Holdings Group Ltd, and Sino Biopharmaceutical Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cyclin-dependent kinase 4
  • The pipeline guide reviews pipeline therapeutics for Cyclin-dependent kinase 4 by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cyclin-dependent kinase 4 therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cyclin-dependent kinase 4 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Cyclin-dependent kinase 4

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cyclin-dependent kinase 4
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cyclin-dependent kinase 4 pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Aucentra Therapeutics Pty Ltd
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
Cothera Bioscience Pty Ltd
CStone Pharmaceuticals Co Ltd
Eli Lilly and Co
ESSA Pharma Inc
Fochon Pharmaceutical Ltd
G1 Therapeutics Inc
Guangzhou BeBetter Medicine Technology Co Ltd
HEC Pharma Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Nuvation Bio Inc
Onconova Therapeutics Inc
OnQuality Pharmaceuticals LLC
Pfizer Inc
Prelude Therapeutics Inc
Qilu Regor Therapeutics Inc
Rhizen Pharmaceuticals SA
Rizen (Suzhou) Biosciences Co Ltd
Sanofi
SATT Conectus Alsace SAS
Shanghai Haihe Biopharma Co Ltd
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
SignalRx Pharmaceuticals Inc
Sihuan Pharmaceutical Holdings Group Ltd
Simcere Pharmaceutical Group Ltd
Sino Biopharmaceutical Ltd
Tetranov International Inc
Tiziana Life Sciences Plc
Travecta Therapeutics Inc
ViroStatics SRL

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) – Overview

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) – Companies Involved in Therapeutics Development

Aucentra Therapeutics Pty Ltd

Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

Cothera Bioscience Pty Ltd

CStone Pharmaceuticals Co Ltd

Eli Lilly and Co

ESSA Pharma Inc

Fochon Pharmaceutical Ltd

G1 Therapeutics Inc

Guangzhou BeBetter Medicine Technology Co Ltd

HEC Pharma Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Nuvation Bio Inc

Onconova Therapeutics Inc

OnQuality Pharmaceuticals LLC

Pfizer Inc

Prelude Therapeutics Inc

Qilu Regor Therapeutics Inc

Rhizen Pharmaceuticals SA

Rizen (Suzhou) Biosciences Co Ltd

Sanofi

SATT Conectus Alsace SAS

Shanghai Haihe Biopharma Co Ltd

Shanghai Haishi Biopharmaceutical Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shanghai Pharmaceutical Group Co Ltd

Shanghai Xunhe Pharmaceutical Technology Co Ltd

Shengke Pharmaceuticals (Jiangsu) Ltd

SignalRx Pharmaceuticals Inc

Sihuan Pharmaceutical Holdings Group Ltd

Simcere Pharmaceutical Group Ltd

Sino Biopharmaceutical Ltd

Tetranov International Inc

Tiziana Life Sciences Plc

Travecta Therapeutics Inc

ViroStatics SRL

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) – Drug Profiles

abemaciclib – Drug Profile

Product Description

Mechanism Of Action

History of Events

AU-294 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AU-314 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BEBT-209 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BPI-1178 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BPI-16350 – Drug Profile

Product Description

Mechanism Of Action

History of Events

cetuximab + cobimetinib + palbociclib – Drug Profile

Product Description

Mechanism Of Action

CS-3002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

dalpiciclib – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drug to Inhibit CDK4 for Ovarian Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

ebvaciclib – Drug Profile

Product Description

Mechanism Of Action

History of Events

ETH-155008 – Drug Profile

Product Description

Mechanism Of Action

History of Events

FCN-437c – Drug Profile

Product Description

Mechanism Of Action

History of Events

GZ-381 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HEC-80797 – Drug Profile

Product Description

Mechanism Of Action

HS-10342 – Drug Profile

Product Description

Mechanism Of Action

History of Events

JS-101 – Drug Profile

Product Description

Mechanism Of Action

JS-104 – Drug Profile

Product Description

Mechanism Of Action

History of Events

lerociclib – Drug Profile

Product Description

Mechanism Of Action

History of Events

milciclib – Drug Profile

Product Description

Mechanism Of Action

History of Events

NUV-422 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ON-108110 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ON-123300 – Drug Profile

Product Description

Mechanism Of Action

History of Events

OQL-051 – Drug Profile

Product Description

Mechanism Of Action

History of Events

palbociclib – Drug Profile

Product Description

Mechanism Of Action

History of Events

PF-07220060 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PRT-3645 – Drug Profile

Product Description

Mechanism Of Action

RGT-419B – Drug Profile

Product Description

Mechanism Of Action

ribociclib succinate – Drug Profile

Product Description

Mechanism Of Action

History of Events

RMC-4550 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RP-13XXX – Drug Profile

Product Description

Mechanism Of Action

SCR-8079 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit CDK4 and CDK6 for Oncology – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit CDK4/6 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Target AR, CDK4 and CDK6 for Breast Cancer – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit CDK4 for Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CDK4 for Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections – Drug Profile

Product Description

Mechanism Of Action

History of Events

SRX-3177 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TQ-05510 – Drug Profile

Product Description

Mechanism Of Action

TQB-3616 – Drug Profile

Product Description

Mechanism Of Action

History of Events

trilaciclib – Drug Profile

Product Description

Mechanism Of Action

History of Events

TVT-227 – Drug Profile

Product Description

Mechanism Of Action

TVT-243 – Drug Profile

Product Description

Mechanism Of Action

TVT-287 – Drug Profile

Product Description

Mechanism Of Action

TY-302 – Drug Profile

Product Description

Mechanism Of Action

voruciclib – Drug Profile

Product Description

Mechanism Of Action

History of Events

VS-2370 – Drug Profile

Product Description

Mechanism Of Action

History of Events

XH-30002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

XZP-3287 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) – Dormant Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) – Discontinued Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) – Product Development Milestones

Featured News & Press Releases

Mar 19, 2022: Drug combination shows effectiveness in patients with recurrent ER-positive endometrial cancer

Mar 10, 2022: NEJM publication of Novartis Kisqali data shows longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Mar 10, 2022: EMA recommends extension of therapeutic indications for Abemaciclib

Mar 08, 2022: OnQuality Pharmaceuticals to present preclinical data for OQL-051, a novel chemotherapy-induced diarrhea therapeutic, at AACR

Mar 08, 2022: Lilly announces to present data from Verzenio at 2022 American Association for Cancer Research (AACR)

Feb 24, 2022: Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer

Jan 27, 2022: Health Canada authorizes Verzenio (abemaciclib) as the first and only CDK4/6 inhibitor for patients with HR+ HER2- high risk early breast cancer

Jan 19, 2022: Shanghai Fosun Pharmaceutical: Announcement in relation to the progress of drug clinical trial by a subsidiary

Jan 03, 2022: Hengrui Medicine’s class 1 new drug Isethionate Dalsili Tablets approved for marketing

Dec 28, 2021: Regor Therapeutics announces U.S. FDA authorization to conduct Regor’s first-in-human clinical trial with the next generation targeted inhibitor RGT-419B for oncology

Dec 22, 2021: Simcere Pharmaceutical Group: Voluntary announcement in relation to the inclusion of Trilaciclib for injection as a priority review drug by CDE

Dec 16, 2021: G1 Therapeutics announces expansion of COSELA (Trilaciclib) sales force

Dec 15, 2021: Nuvation Bio receives FDA Fast Track Designation for NUV-422 for the treatment of high-grade gliomas, including glioblastoma multiforme

Dec 13, 2021: Nuvation Bio announces FDA Clearance of investigational new drug application for NUV-422 for the Treatment of Prostate Cancer

Dec 09, 2021: ESMO: Two years of adjuvant Palbociclib added to endocrine therapy does not improve outcomes in early breast cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Indications, 2022 (Contd..4)

Number of Products under Development by Indications, 2022 (Contd..5)

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Products under Development by Companies, 2022 (Contd..9)

Products under Development by Companies, 2022 (Contd..10)

Products under Development by Companies, 2022 (Contd..11)

Products under Development by Companies, 2022 (Contd..12)

Products under Development by Companies, 2022 (Contd..13)

Products under Development by Companies, 2022 (Contd..14)

Products under Development by Companies, 2022 (Contd..15)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Aucentra Therapeutics Pty Ltd, 2022

Pipeline by Beta Pharma Inc, 2022

Pipeline by Betta Pharmaceuticals Co Ltd, 2022

Pipeline by Cothera Bioscience Pty Ltd, 2022

Pipeline by CStone Pharmaceuticals Co Ltd, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by ESSA Pharma Inc, 2022

Pipeline by Fochon Pharmaceutical Ltd, 2022

Pipeline by G1 Therapeutics Inc, 2022

Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2022

Pipeline by HEC Pharma Co Ltd, 2022

Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Pipeline by MEI Pharma Inc, 2022

Pipeline by Novartis AG, 2022

Pipeline by Nuvation Bio Inc, 2022

Pipeline by Onconova Therapeutics Inc, 2022

Pipeline by OnQuality Pharmaceuticals LLC, 2022

Pipeline by Pfizer Inc, 2022

Pipeline by Prelude Therapeutics Inc, 2022

Pipeline by Qilu Regor Therapeutics Inc, 2022

Pipeline by Rhizen Pharmaceuticals SA, 2022

Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022

Pipeline by Sanofi, 2022

Pipeline by SATT Conectus Alsace SAS, 2022

Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022

Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, 2022

Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022

Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022

Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2022

Pipeline by Shengke Pharmaceuticals (Jiangsu) Ltd, 2022

Pipeline by SignalRx Pharmaceuticals Inc, 2022

Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, 2022

Pipeline by Simcere Pharmaceutical Group Ltd, 2022

Pipeline by Sino Biopharmaceutical Ltd, 2022

Pipeline by Tetranov International Inc, 2022

Pipeline by Tiziana Life Sciences Plc, 2022

Pipeline by Travecta Therapeutics Inc, 2022

Pipeline by ViroStatics SRL, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.